Also known as GLOW blend · GHK-Cu + BPC-157 + TB-500
A three-peptide skin-and-recovery blend typically combining GHK-Cu, BPC-157, and TB-500.
Research refreshed
GLOW is a marketed blend that typically combines the copper tripeptide GHK-Cu with BPC-157 and TB-500 — pairing a skin-and-collagen peptide with the two most-studied tissue-repair peptides. It is positioned around skin quality and recovery. Exact components and ratios are defined by the vendor and are not standardized, and no controlled study has tested the mixture; the components are each research compounds studied individually.
GLOW sits at the overlap of the cosmetic and repair literatures: GHK-Cu is studied for collagen synthesis, matrix remodeling, and skin appearance, while BPC-157 and TB-500 are the recovery peptides it is usually bundled with. The name reflects the skin-quality framing, and the blend is marketed as a single convenience vial.
As with any blend, the combined formulation has no trial behind it, and vendor formulas differ — the GHK-Cu-plus-BPC-157-plus-TB-500 recipe is the common one but not a specification. Treat the composition as vendor-defined. None of the components is FDA-approved, and this is a research reference rather than a cosmetic or medical recommendation.
GHK-Cu: copper delivery, collagen and extracellular-matrix gene regulation, antioxidant signaling. BPC-157 and TB-500: angiogenesis and actin-driven cell migration (see their pages). Combined effect is proposed, not measured.
Behind every vial of GLOW is the same exacting pipeline every research peptide runs — but the chemistry plays out differently for this molecule. Here is how GLOW, specifically, is brought into being.
GLOW begins not as a powder but as a specification. Before a single bond is made, the target sequence, salt form, and purity threshold are written down as the contract the finished material must meet.
GLOW is assembled by solid-phase peptide synthesis — the chain grows one protected residue at a time on resin, and what you fail to build cleanly here you pay to remove later.
The crude mixture — GLOW plus its deletions and side products — is then separated on preparative HPLC, and where the cut is taken decides the difference between a genuinely pure peptide and a barely-passable one.
A real batch of GLOW proves itself: identity confirmed by mass spectrometry, purity read directly off an analytical HPLC trace, water and counterion content measured. That batch-specific certificate of analysis is the only honest way to know what is actually in a vial of GLOW — and a short, cold, accountable chain of custody is how that purity survives the trip to your bench.
A physical mixture of three separately made compounds — GHK-Cu (a copper-complexed tripeptide), BPC-157, and TB-500 — so there is no single synthesis or purity number. A meaningful certificate assays each component on its own, states the amount of each, and for the GHK-Cu portion confirms copper content. The more components share a vial, the more the blend’s real-world stability departs from anything characterized.
Don't judge a vial by its cake. A fluffy, good-looking lyophilized powder reflects bulking agents and freeze-drying parameters — not purity. Insist on a batch-specific certificate of analysis.
Recent clinical trials and publications mentioning GLOW blend, pulled automatically from ClinicalTrials.gov and PubMed and refreshed daily. Listings are unfiltered search results, not curated endorsements.
It typically combines GHK-Cu, BPC-157, and TB-500, though exact components and ratios are set by the vendor and are not standardized.
Skin quality and recovery — pairing a collagen/skin peptide (GHK-Cu) with two tissue-repair peptides. These are research framings, not proven outcomes.
KLOW is generally the same idea with a fourth component (KPV) added; GLOW is the three-peptide version. Vendor formulas vary.
No — the components are research compounds and the blend is not FDA-approved. This page is a research and educational reference.
GLOW is a blend. Each component is a single compound with its own catalog monograph — purity, mechanism, and research are documented per component below.
Endogenous copper-binding tripeptide widely studied in skin and hair biology.
ViewSynthetic gastric pentadecapeptide investigated for tendon, ligament, and GI repair.
ViewThe seven-residue actin motif of thymosin β4 (LKKTETQ) — the fragment sold as a stand-in for the full 43-residue protein.
ViewA 43-residue actin buffer. It holds G-actin so cells can move, and its first four residues become the anti-fibrotic peptide Ac-SDKP.
ViewA 27-residue single-chain relaxin-2 analog and selective RXFP1 agonist — a simplified relaxin mimetic studied for anti-fibrotic effects.
ViewCopper-binding tripeptide (Ala-His-Lys) studied for hair-follicle stimulation and dermal repair.
ViewDosing protocols, mechanism, comparisons, and the latest trials — citation-backed answers grounded in PubMed, PubChem, and ClinicalTrials.gov.